Finanzen von Bioventus Inc. (BVS)BVSBioventus Inc.

Bioventus Inc. (BVS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Pain Treatments, accounting for 48.0% of total sales, equivalent to $63.43M. Other significant revenue streams include Surgical solutions and Restorative Therapies. Understanding this composition is critical for investors evaluating how BVS navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Bioventus Inc. maintains a gross margin of 68.29%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 12.42%, while the net margin is 23.63%. These profitability ratios, combined with a Return on Equity (ROE) of 27.96%, provide a clear picture of how effectively BVS converts its operational activities into shareholder value.

In the context of the broader market, BVS competes directly with industry leaders such as PRCT and IRMD. With a market capitalization of $1.20B, it holds a significant position in the sector. When comparing efficiency, BVS's gross margin of 68.29% stands against PRCT's 66.01% and IRMD's 74.07%. Such benchmarking helps identify whether Bioventus Inc. is trading at a premium or discount relative to its financial performance.

In Q2 2026, Bioventus reported a revenue of $153 million, a 4% increase year-over-year, and a significant net income of $33.44 million, reflecting strong operational performance and cash flow generation.